Literature DB >> 33257819

Diversity of KIRs in invasive breast cancer patients and healthy controls along with the clinical significance in ER/PR/HER2+ patients.

Marjan Hematian Larki1,2, Shaghik Barani1,2, Abdol-Rasoul Talei3, Abbas Ghaderi4,5.   

Abstract

Killer cell immunoglobulin-like receptors (KIR) consists of activating and inhibitory genes are essential for natural killer cell education. To determine the association of KIRs with susceptibility to invasive Breast cancer (BC), genotyping of 16 KIRs was performed by sequence-specific primers-polymerase chain reaction in 226 confirmed cases of BC with defined estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) status and 226 healthy controls (CNs). We observed a lower frequency of 2DL1 and 2DS4del along with increased frequency of 2DS4fl in cases compared to CNs. Further analysis revealed a higher frequency of KIR2DL2, 2DS1, 2DS2,3DS1 in ER+ cases, 2DL2, 2DL5 in PR+ and 2DL1 in HER2+ cases compared to CNs. The detrimental role of KIR2DS4fl was observed in ER+ and PR+ cases whereas 2DS4del confers protection against ER+, PR+, and HER2+ cases. We noted the predisposing role of Bx genotype, KIR2DS1, 2DS2, 2DS5, 2DL2, 2DL5 for lymphatic invasion in ER+ cases along with a higher rate of lymph node metastasis (LNM) in carriers of Bx genotype and KIR2DS1 in ER+ cases. We suggest a link between B haplotype associated genes with the increased risk of lymphatic invasion and LNM, particularly in ER+ cases of BC.

Entities:  

Year:  2020        PMID: 33257819     DOI: 10.1038/s41435-020-00117-1

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  3 in total

1.  Coexistence of inhibitory and activating killer-cell immunoglobulin-like receptors to the same cognate HLA-C2 and Bw4 ligands confer breast cancer risk.

Authors:  Elham Ashouri; Karan Rajalingam; Shaghik Barani; Shirin Farjadian; Abbas Ghaderi; Raja Rajalingam
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

2.  KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer.

Authors:  Elena Muraro; Mariangela De Zorzi; Gianmaria Miolo; Davide Lombardi; Simona Scalone; Simon Spazzapan; Samuele Massarut; Tiziana Perin; Riccardo Dolcetti; Agostino Steffan; Valli De Re
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

3.  KIR-HLA gene diversities and susceptibility to lung cancer.

Authors:  Marjan Hematian Larki; Elham Ashouri; Shaghik Barani; Seiyed Mohammad Ali Ghayumi; Abbas Ghaderi; Raja Rajalingam
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.